These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9303400)

  • 1. Structure-absorption relationships of a series of 6-fluoroquinolones.
    Escribano E; Calpena AC; Garrigues TM; Freixas J; Domenech J; Moreno J
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1996-2000. PubMed ID: 9303400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal absorption of a series of 6-fluoquinolone derivatives: a comparative study.
    Escribano E; Freixas J; Colom H; Lauroba J; Calpena AC; Domenech J
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():57-60. PubMed ID: 1820936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the chromatographic capacity factor (log k') as an index of lipophilicity in the antibacterial activity of a series of 6-fluoroquinolones. Relationship between physico-chemical and structural properties and their hydrophobicity.
    Martorell C; Calpena AC; Escribano E; Poblet JM; Freixas J
    J Chromatogr A; 1993 Dec; 655(2):177-84. PubMed ID: 8111471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones.
    Merino V; Freixas J; del Val Bermejo M; Garrigues TM; Moreno J; Plá-Delfina JM
    J Pharm Sci; 1995 Jun; 84(6):777-82. PubMed ID: 7562422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical properties of enrofloxacin.
    Lizondo M; Pons M; Gallardo M; Estelrich J
    J Pharm Biomed Anal; 1997 Aug; 15(12):1845-9. PubMed ID: 9278889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a biophysical drug absorption model by the PATQSAR system.
    Bermejo M; Merino V; Garrigues TM; Pla Delfina JM; Mulet A; Vizet P; Trouiller G; Mercier C
    J Pharm Sci; 1999 Apr; 88(4):398-405. PubMed ID: 10187749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
    Piddock LJ; Jin YF; Ricci V; Asuquo AE
    J Antimicrob Chemother; 1999 Jan; 43(1):61-70. PubMed ID: 10381102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment.
    Cabrera Pérez MA; González Díaz H; Fernández Teruel C; Plá-Delfina JM; Bermejo Sanz M
    Eur J Pharm Biopharm; 2002 May; 53(3):317-25. PubMed ID: 11976020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.
    Takenouchi T; Tabata F; Iwata Y; Hanzawa H; Sugawara M; Ohya S
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1835-42. PubMed ID: 8843290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutic evaluation of some 4-quinolone derivatives.
    Mrhar A; Primozic S; Bogataj M; Kozjek F
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():473-7. PubMed ID: 1820926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release kinetics and up-take studies of model fluoroquinolones from carbomer hydrogels.
    Vilches AP; Jimenez-Kairuz A; Alovero F; Olivera ME; Allemandi DA; Manzo RH
    Int J Pharm; 2002 Oct; 246(1-2):17-24. PubMed ID: 12270605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolone resistance in potentially pathogenic and non-pathogenic Escherichia coli strains isolated from healthy ruminants.
    Orden JA; Ruiz-Santa-Quiteria JA; Cid D; Díez R; Martínez S; de la Fuente R
    J Antimicrob Chemother; 2001 Sep; 48(3):421-4. PubMed ID: 11533010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity-bioavailability balance in oral drug development for a selected group of 6-fluoroquinolones.
    Taléns-Visconti R; Garrigues TM; Cantón E; Freixas J; Martín-Villodre A; Plá-Delfina JM
    J Pharm Sci; 2002 Nov; 91(11):2452-64. PubMed ID: 12379931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation and killing kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa.
    Asuquo AE; Piddock LJ
    J Antimicrob Chemother; 1993 Jun; 31(6):865-80. PubMed ID: 8360125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells.
    Fernandez-Teruel C; Gonzalez-Alvarez I; Casabó VG; Ruiz-Garcia A; Bermejo M
    J Drug Target; 2005 Apr; 13(3):199-212. PubMed ID: 16036308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Shevchenko AA; Cornaglia G
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1281-7. PubMed ID: 9174184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.